The masthead
About Dose Brief
The 5-minute GLP-1 briefing — prices, shortages, and provider moves.
Dose Brief is an independent newsroom, not a pharmacy or a telehealth company. We track what GLP-1 care actually costs week to week, whether the medications are in supply, and how the providers behind them change — then we distill it into a short brief you can read in five minutes.
Everything here is scored on our published Brief Score — the same six factors for every provider. Assume any provider we list may compensate us, and a commission never buys a higher score. Read the disclosure for exactly how the desk is funded, and the editorial policy for the standards every dispatch is held to. What we do with anything you send us is covered by our privacy policy, and the rules for using the site itself are in the terms.
If you already know what you are shopping for, the scored field is filed by question — start at the GLP-1 price rankings and pick the one that matches yours.
The desk
Edited by The Dose Brief Desk, News Editor. A plain-English newsroom tracking GLP-1 prices, supply, and provider changes — and ranking the telehealth providers behind them on a published six-factor Brief Score.
Contact
Corrections, tips, or questions about the desk go to editor@dosebrief.com. We read everything and answer what we can.
Dose Brief is editorial information, not medical advice. Compounded GLP-1 medications are not FDA-approved finished drug products — talk to a licensed clinician before starting any weight-management medication. See our medical disclaimer.